Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift...
COVID-19
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation (“Reverse Stock Split”)
ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Luxury Addiction Rehab Expands Services Amid Rebranding
Private addiction and dual diagnosis treatment center Annandale Behavioral Health develops a comprehensive continuum of care for drug and alcohol...
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose...
Gilead Sciences with Emma’s Story: Self-Advocacy in Breast Cancer
NORTHAMPTON, MA / ACCESSWIRE / January 16, 2024 / "It's an experience that I hope no one goes through, but...
Women’s Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
Third annual Hologic Global Women’s Health Index shows billions of women untested for life-threatening conditions, emotional health worsening and nearly...
CLS Holdings USA Inc. (“CLSH”) Announces Repayment of $3,875,094 in Principal Debenture Obligations
LAS VEGAS, NV / ACCESSWIRE / January 16, 2024 / This Debt Retirement eliminates a total of $4,340,101 in Principal...
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
TORONTO, ON / ACCESSWIRE / January 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), is a...
Nanox Mourns Death of Its Founder, Ran Poliakine
PETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative...
Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD
Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024LOS ANGELES, Jan. 16, 2024...
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role
Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine marketsPOMPANO BEACH, Fla., Jan. 11,...
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
The Joint Corp. Reports 2023 Operating Metrics
- Grows Annual System-Wide Sales 12%, Compared to 2022 -- Increases Comp Sales of 4%, Compared to 2022 - -...
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is...
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality...
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and...